Chemistry:Ruzinurad
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H12BrNO2S |
| Molar mass | 338.22 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ruzinurad (SHR4640) is a selective urate transporter 1 (URAT1) inhibitor in development for hyperuricaemia and gout. It is developed by Jiangsu Hengrui.[1][2][3][4][5][6]
References
- ↑ Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian et al. (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. ISSN 1462-0332. PMID 33693494. https://pubmed.ncbi.nlm.nih.gov/33693494/.
- ↑ Wang, Chenjing; Yu, Qing; Jiang, Xin; Deng, Yujie; Sun, Feifei; Li, Xin; Tao, Ye; Lin, Pingping et al. (February 2023). "A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia". The Journal of Clinical Pharmacology 63 (2): 239–249. doi:10.1002/jcph.2159. PMID 36131360.
- ↑ Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian et al. (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. PMID 33693494.
- ↑ Liang, Beibei; Wang, Jin; Bai, Nan; Zhuo, Jiaju; Wang, Rui; Lin, Hongda; Cai, Yun (April 2023). "Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of SHR4640, a Selective Urate Transporter 1 Inhibitor, in Healthy Chinese Male Volunteers". Clinical Pharmacology in Drug Development 12 (4): 392–396. doi:10.1002/cpdd.1191. ISSN 2160-7648. PMID 36317751. https://pubmed.ncbi.nlm.nih.gov/36317751/.
- ↑ "A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout". https://www.clinicaltrials.gov/study/NCT04956432.
- ↑ Tang, Honghu; Cui, Beibei; Chen, Yiyu; Chen, Lin; Wang, Zhihong; Zhang, Ning; Yang, Yanlan; Wang, Xiaodong et al. (January 2022). "Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study" (in en). Therapeutic Advances in Musculoskeletal Disease 14: 1759720X2110673. doi:10.1177/1759720X211067304. ISSN 1759-720X. PMID 35126684.
 |  |
